Caremo Granted "Nanjing Topical Transdermal Drug Delivery Engineering Research Center" Accreditation

In August 2024, Caremo achieved another significant milestone with its accreditation as the "Nanjing Topical Transdermal Drug Delivery Engineering Research Center"—a follow-up to its 2023 recognition as the "Nanjing Engineering Technology Research Center for Special Dosage Forms."

This accreditation was awarded in compliance with the Nanjing Engineering Research Center Management Measures (Ning Development and Reform Regulation [2011] No. 1020) and the 2024 Nanjing Engineering Research Center Application Guidelines (Ning Development and Reform High-Tech [2024] No. 362). Following rigorous evaluation processes—including enterprise application submission, regional review and recommendation, formal compliance review, and expert evaluation—Caremo Pharmaceutical’s successful accreditation reflects both the Nanjing Municipal Development and Reform Commission’s and expert review panel’s recognition of the company’s technical expertise and innovation capabilities in pharmaceutical formulation research. It also signifies another milestone in Caremo’s scientific advancement.

Adhering to international standards, Caremo Pharmaceutical provides end-to-end CMC (Chemistry, Manufacturing, and Controls) development services to global pharmaceutical partners, accelerating clients’ R&D timelines, overcoming technical challenges, and enabling swift commercialization. Through sustained investment and innovation in formulation research, Caremo has established multiple advanced technology platforms, including:

- Transdermal drug delivery technology platform

- Sustained- and controlled-release formulation platform

- Fixed-dose combination drug development platform

- Solubility enhancement platform for poorly soluble drugs

- Oral fast-dissolving technology platform

- Softgel capsule technology platform

- Nasal spray formulation development platform

These platforms empower Caremo to address diverse client needs with comprehensive, one-stop formulation development services.

Moving forward, Caremo Pharmaceutical will deepen its focus on innovative drug R&D technologies, strengthen industry-academia synergies, and accelerate drug development timelines while reducing costs and enhancing efficiency. Aligned with its mission—“Born for health, Empowered for innovation”—Caremo aims to drive the growth of China’s pharmaceutical industry and deliver transformative solutions for global healthcare challenges.